Evidence map›Paper›PMID 41346773›Full record

ArticleJournal of the advanced practitioner in oncology2025

The Factor Approach: Coagulation Treatment Optimization and Recommendations (FACTOR).

Sara Leidy, Zahra Mahmoudjafari

Abstract read
In one paragraph

Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sara LeidyFrom The University of Kansas Cancer Center, Westwood, Kansas.
Zahra MahmoudjafariFrom The University of Kansas Cancer Center, Westwood, Kansas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exogenous blood factor products, such as recombinant or human-derived factor VIIa, factor VIII, factor IX, and von Willebrand factor, are crucial for treating various bleeding disorders, but come with high risks and costs. Effective formulary management and development of institutional evidence-based guidelines for blood factor products are essential to maximize patient outcomes and minimize adverse events through an interprofessional approach. This article details the steps and considerations involved for the development of a blood factor product formulary and management at an academic medical center.

Identifiers

PMID41346773
PMCPMC12673994

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.